Compare GLPI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLPI | EXEL |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 11.7B |
| IPO Year | 2013 | 2000 |
| Metric | GLPI | EXEL |
|---|---|---|
| Price | $43.96 | $41.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $52.13 | $46.45 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | 2.79 | ★ 57.95 |
| EPS | ★ 2.95 | 2.78 |
| Revenue | ★ $1,594,752,000.00 | $452,477,000.00 |
| Revenue This Year | $8.73 | $13.66 |
| Revenue Next Year | $5.07 | $13.39 |
| P/E Ratio | ★ $15.21 | $15.24 |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $41.17 | $32.38 |
| 52 Week High | $51.44 | $48.74 |
| Indicator | GLPI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 26.75 | 47.15 |
| Support Level | $42.45 | $40.34 |
| Resistance Level | $43.90 | $41.75 |
| Average True Range (ATR) | 0.92 | 0.95 |
| MACD | -0.50 | 0.14 |
| Stochastic Oscillator | 0.18 | 40.30 |
Gaming and Leisure Properties Inc, or GLP, is a self-administered and self-managed Pennsylvania real estate investment trust (REIT). It is engaged in acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The company also extends loans that produce fixed or variable returns, which may convert into leased rent upon project completion or stabilization. Its portfolio consists of gaming and related facilities and amenities such as Ameristar Black Hawk, Bally's Casino, Argosy Casino Alton, Bally's Chicago, Hollywood Casino Aurora, and others located across different states in the United States.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.